Goldman Sachs’s Moleculin Biotech MBRX Stock Holding History

Goldman Sachs’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-26	Closed	-$6.76K	–	6674
2025 Q3	$6.76K	Buy	+26	New	+$7.02K	﹤0.01%	6267
2022 Q1	–	Sell	-2	Closed	-$22K	–	6768
2021 Q4	$22K	Buy	+2	New	+$35.5K	﹤0.01%	6359
2021 Q3	–	Sell	-3	Closed	-$94K	–	6398
2021 Q2	$94K	Buy	+3	New	+$81.9K	﹤0.01%	5960
2017 Q2	–	Hold	0	–	-$20K	–	6873
2017 Q1	–	Hold	0	–	–	–	6515

Other funds holding MBRX

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EFG International Zurich $5.46B AUM

Pinnacle Wealth Planning Services Mansfield, Ohio $1.03B AUM 22.32% 1-Year Est. Return

Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return

Goldman Sachs's MBRX Position: Q4 2025 in Review

Goldman Sachs sold out of Moleculin Biotech (MBRX) in Q4 2025, closing a stake of 26 shares — an estimated $6.76K sold.

Goldman Sachs first reported a position in MBRX in Q2 2021 and held it in 3 quarters. The position peaked at $94K in Q2 2021. 14 funds tracked by Wall St. Rank hold MBRX as of Q4 2025.

Goldman Sachs reported no remaining Moleculin Biotech position as of Q4 2025 after selling out during the quarter.
Goldman Sachs sold 26 Moleculin Biotech shares in Q4 2025, an estimated $6.76K.
Goldman Sachs first reported a position in Moleculin Biotech in Q2 2021 and held it in 3 quarters.
Goldman Sachs's Moleculin Biotech position peaked at $94K in Q2 2021.
14 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2025.

Based on Goldman Sachs's 13F filing for Q4 2025, filed 10 Feb 2026.